Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are now a cornerstone of systemic treatment for hepatocellular carcinoma (HCC). However, their efficacy is blunted by mechanisms of tumour resistance in many patients. This review reports on the state of the art of resistance to ICIs, focusing on H...

Descripción completa

Detalles Bibliográficos
Autores principales: De Lorenzo, Stefania, Tovoli, Francesco, Trevisani, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564277/
https://www.ncbi.nlm.nih.gov/pubmed/36230538
http://dx.doi.org/10.3390/cancers14194616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564277/
https://www.ncbi.nlm.nih.gov/pubmed/36230538
http://dx.doi.org/10.3390/cancers14194616

Ejemplares similares